Boston Scientific acquires Lumenis surgical line for $1B

MedTech News: Boston Scientific is set to acquire the global surgical business of Lumenis for $1.07 billion.

Boston Scientific will acquire a surgical portfolio consisting of laser systems, accessories and fibers for urology and otolaryngology procedures, led by Lumenis’ Moses laser used as a minimally invasive treatment for patients with kidney stones. The private equity firm that currently own Lumenis will keep ownership of Lumenis’ global aesthetics and ophthalmology businesses.

Lumenis’ laser portfolio has posted a double-digit compound annual growth rate from 2015-2019, and the surgical business is expected to bring in about $200 million in net sales in 2021, according to the deal announcement.

The MOSES laser technology, paired with our LithoVue Single-Use Digital Flexible Ureteroscope and comprehensive kidney stone management portfolio, will enable execution of our strategy for our stone franchise,” said Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, Boston Scientific. “With double-digit compound annual growth from 2015 to 2019, we look forward to adding the innovative Lumenis laser portfolio, talented employees and surgical laser centre of excellence to our organisation. The acquisition will expand our global footprint throughout Europe and Asia and accelerate the delivery of our robust stone management offerings to more urologists – ultimately serving more patients worldwide – while also improving our top-line growth and margins.”

Boston Scientific has had a relationship with Lumenis for more than 20 years and currently sells the Lumenis urology laser portfolio in the U.S. and Japan through a distribution arrangement. Upon completion of the acquisition, in the second half of 2021, Boston Scientific will sell these lasers and fibers – as well as the otolaryngology laser portfolio – to all geographies including high-growth regions like China. 

“We take great pride in our heritage of innovation in surgical laser solutions which are helping millions of patients worldwide,” said Tzipi Ozer-Armon, chief executive officer, Lumenis. “Notably the proprietary, patent-protected MOSES technology has revolutionized urology laser procedures by improving the clinical efficacy and efficiency for kidney stones. We are confident that Boston Scientific, as a global leader in urology, and our long-time commercial partner, is the best organisation to carry this legacy forward.”